The EGFR mAb inhibitors, namely cetuximab and panitumumab, may be the pertinent choice in combating chemotherapy-resistant NB, as all patients in the chemoresistance group had wild-type KRAS, indicating responsiveness. The gene discussed is KRAS; the disease is neuroblastoma.